Research summary ·
Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis.
Written based on 1 research study on PubMed, searched on 3 Nov 2026.
What was studied
This review pooled studies of antibody-drug conjugates in lung cancer. The people had non-small cell lung cancer. Some also had cancer that had spread to the brain. The team included 13 studies with 3,191 patients. Of these, 905 had brain spread. They looked at response rates and severe side effects.
What they found
The abstract gives pooled response rates for the whole body. It also gives rates for the brain. Drugs that target HER2 showed substantial activity. Drugs that target TROP-2 and HER3 also showed activity. Response in the body did not differ between patients with and without brain spread.
What it means for patients
The authors say these drugs were active in the body and in the brain. They say this held for people with brain spread. They see these drugs as a treatment option for this group.
Why it is not certain yet
The abstract says people with brain spread are often left out of trials. The abstract does not say how the studies were designed. Different drug types were pooled in one review. A review can only be as good as the studies in it.
Source
Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis.
PubMed · PMID 42815252We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Lung cancer publications